恆瑞醫藥(600276.SH):4名董事及高管擬合計減持不超66.48萬股
格隆匯11月1日丨恆瑞醫藥(600276.SH)公佈,因個人資金需求,董事及高級管理人員周雲曙、袁開紅、孫杰平、劉笑含計劃在2019年11月25日至2020年5月22日期間以集中競價交易方式減持公司股份合計不超過約66.48萬股(佔公司股份總數的0.0150%)。
減持計劃實施期間,公司若發生派發紅利、送紅股、轉增股本、增發新股或配股等股本除權、除息事項的,減持數量將進行相應調整。減持價格將按照減持實施時的市場價格確定。
截至公告披露之日,公司董事及高級管理人員周雲曙、袁開紅、孫杰平、劉笑含合計持有公司股份約601.79萬股,佔公司股份總數的0.1361%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.